Investigational drug · Phase 3
IgPro20
Also called: Immune Globulin 20% Liquid
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Secondary Immune Deficiency.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
18
Any phase or sponsor naming "IgPro20"
First trial start
2026
Sep 15, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IgPro20", any sponsor or status.
- Phase 312
Conditions studied
As listed on its trial records.
- Secondary Immune Deficiency
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "IgPro20" as an intervention, largest first.
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)Pivotal-lookingCompleted
CSL BehringIndustry
NCT01545076 · 208 participants · Start Mar 2012 · Primary completion Sep 2016
Drug: IgPro20 (low dose); Placebo and 2 more · For: Chronic Inflammatory Demyelinating Polyneuropathy; Polyradiculoneuropathy
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 91 sites in all
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)Pivotal-lookingTerminated
CSL BehringIndustry
NCT04044690 · 134 participants · Start Oct 21, 2019 · Primary completion Dec 2, 2024
Drug: human immunoglobulin G; Placebo · For: Dermatomyositis
Sites: Glendale, Arizona; Phoenix, Arizona; Los Angeles, California · 76 sites in all
CSL BehringIndustry
NCT04672733 · 100 participants (planned) · Start Jun 10, 2022 · Primary completion Dec 2027
Drug: Hizentra · For: Chronic Inflammatory Demyelinating Polyneuropathy
Sites: Amiens, France; Angers, France; Aubagne, France · 27 sites in all
- Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and HypogammaglobulinemiaPivotal-lookingRecruiting
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT06976476 · 100 participants (planned) · Start May 8, 2025 · Primary completion May 8, 2029
Drug: IgPro20 · For: Multiple Myeloma; Hypogammaglobulinemia; Hypogammaglobulinemia, Acquired
Sites: Atlanta, Georgia; Basking Ridge, New Jersey; Middletown, New Jersey · 9 sites in all
- Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Pivotal-lookingCompleted
CSL BehringIndustry
NCT02027701 · 82 participants · Start Jul 30, 2014 · Primary completion Jul 10, 2017
Drug: IgPro20 · For: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Sites: Birmingham, Alabama; Los Angeles, California; Kansas City, Kansas · 33 sites in all
- Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting TherapiesPivotal-lookingRecruiting
CSL BehringIndustry
NCT07648264 · 63 participants (planned) · Start Sep 15, 2026 · Primary completion Sep 27, 2029
Drug: IgPro20 · For: Secondary Immune Deficiency
Sites: Orange, California; Denver, Colorado; Coral Springs, Florida · 60 sites in all
- Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement TherapyPivotal-lookingCompleted
CSL BehringIndustry
NCT00542997 · 51 participants · Start Sep 2007 · Primary completion Aug 2009
Drug: Human Normal Immunoglobulin for Subcutaneous Administration (IGSC) · For: Common Variable Immunodeficiency; X-linked Agammaglobulinemia; Autosomal Recessive Agammaglobulinemia
Sites: Paris, France; Berlin, Germany; Düsseldorf, Germany · 19 sites in all
- Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement TherapyPivotal-lookingCompleted
CSL BehringIndustry
NCT00419341 · 49 participants · Start Nov 2006 · Primary completion Oct 2008
Drug: Human Normal Immunoglobulin for Subcutaneous Administration · For: Primary Immune Deficiency
Sites: Los Angeles, California; Centennial, Colorado; North Palm Beach, Florida · 13 sites in all
CSL BehringIndustry
NCT03033745 · 49 participants · Start Feb 1, 2017 · Primary completion Dec 14, 2018
Drug: IgPro20 · For: Primary Immunodeficiency
Sites: Birmingham, Alabama; Litchfield Park, Arizona; St. Petersburg, Florida · 12 sites in all
- Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)Pivotal-lookingCompleted
CSL BehringIndustry
NCT00751621 · 40 participants · Start Aug 2008 · Primary completion Dec 2011
Drug: IgPro20 · For: Primary Immunodeficiency (PID)
Sites: Paris, France; Berlin, Germany; Freiburg im Breisgau, Germany · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Real-World Health Care Resource Utilization, Adherence, and Persistence Following Subcutaneous IgPro20 Initiation Among US Patients with Chronic Inflammatory Demyelinating Polyneuropathy.
Kuatov B, Weng S, Hubsch A, et al. · Neurol Ther 2026
- Qualitative Research on IgPro20 PreߛFilled Syringe Use Among US Patients with Primary Immunodeficiencies.
Kuatov B, Al-Jassar G, Rudell K, et al. · Patient Prefer Adherence 2026
- Multi-Indication Budget Impact Analysis of Subcutaneous IgPro20 Pre-filled Syringes for the Treatment of Primary Immunodeficiency Syndromes, Secondary Immunodeficiencies, and Chronic Inflammatory Demyelinating Polyneuropathy in Italy.
Kuatov B, MacDonald A, Priest S, et al. · Adv Ther 2026
- Practical Approach to Managing SCIg Treatment in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.
Vu T, Guerra C, Suresh N, et al. · Muscle Nerve 2026
- A Budget Impact Model of Treatment of Primary Immune Deficiency with Immune Globulin Subcutaneous (Human), 20% (IgPro20) (Hizentra).
Mallick R, Carlton R · Pharmacoecon Open 2025
- A phase 2 randomized trial of safety and pharmacokinetics of IgPro20 and IgPro10 in patients with diffuse cutaneous systemic sclerosis.
Denton CP, Kowal-Bielecka O, Proudman SM, et al. · Rheumatology (Oxford) 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.